Moderna has raised $2.6 billion through an upsized note offering to support its cancer-focused work, according to the latest market report. The funding comes as Moderna has faced shifting investor expectations around oncology execution and platform timelines. The cash infusion is positioned to strengthen the company’s ability to run and scale cancer programs while maintaining pipeline momentum. It also signals a willingness to fund development aggressively despite the uneven clinical readthrough seen across cancer immunotherapy cohorts. For biotech portfolios, the financing highlights how capital allocation is increasingly tied to oncology milestones and near-to-midterm clinical catalysts.